A randomized controlled trial of Wharton’s jelly MSC exosomes in 110 chronic diabetic foot ulcer patients, read alongside a 2026 preclinical meta-analysis. What the data support, and what it does not.
CATEGORY ARCHIVE
Research & News
Clinical trials, FDA updates, research breakthroughs, and industry news.
Exosome Storage and Handling: What the Cold Chain Does to Product Quality
What 50 pooled studies say about exosome storage and handling: minus 80 storage, freeze-thaw damage, formulation, and the questions to ask a supplier.
Exosome Dosing: What 66 Clinical Trials Say About Getting the Number Right
A review of 66 registered MSC-derived extracellular vesicle trials finds that route of delivery, not volume, sets the effective dose, and that only six trials reported enough detail to analyse dose at all.
Exosome Certificate of Analysis: The Four Numbers a 2026 Review Says Must Be On It
A 2026 Advanced Science review argues the exosome field must become a quantitative measurement science. Here are the four attributes it says every batch should document.
Exosome Therapy for Skin and Hair: What a 2026 Meta-Analysis of 39 Human Studies Found
Most claims about exosome therapy for skin and hair come from single clinics reporting on their own patients. A...
Stem Cell Therapy for Spinal Cord Injury: 4-Year Results From a World-First Trial
The longest-running safety question in regenerative medicine just received its clearest answer yet. On July 21, 2026,...
What the Latest Research Says About MSC-Derived Exosomes (And What the FDA Says)
A 2025 review of 66 MSC-derived exosome clinical trials shows real progress, but there are still no FDA-approved exosome products. Here is what the research shows, what it does not, and how to read exosome claims as an informed consumer.
The Lancet Publishes Phase 3 HOPE-3 Data: What Peer Review Changes for Exosome Science
The Lancet has published the full Phase 3 HOPE-3 results for deramiocel, an investigational cell therapy whose effect is attributed to secreted exosomes. What independent peer review does and does not establish.
FDA Advisory Panel Votes to Ease Peptide Compounding: What the 2026 Vote Means
An FDA advisory panel voted in July 2026 to ease compounding of peptides like BPC-157 and TB-500. What the recommendation means, and what it does not.
FDA’s 2026 Exosome Enforcement: What the Warning Letters Actually Say
No FDA-approved exosome products exist in 2026. A review of six CBER warning letters shows the agency’s key evidence is marketing copy, not the product.
Stem Cell Therapy for Aging Frailty: What a 2026 Phase 2b Trial Found
A new 2026 Phase 2b trial published in Cell Stem Cell reports that intravenous bone marrow mesenchymal stem cells improved six-minute walk distance in older adults with aging frailty. Here is what the result shows, how to read it honestly, the FDA status, and what to verify before treatment.
Exosome Clinical Trials in 2026: What 90 Human Trials Reveal About Regenerative Medicine
A new 2026 peer-reviewed analysis maps roughly 90 human exosome clinical trials across oncology, neurology, cardiology, and regenerative medicine. Here is what the evidence shows, where MSC-derived exosomes stand, and what to verify before treatment.
Exosomes for Diabetic Foot Ulcers: A 2026 Research Update on Wound Healing Evidence
How exosome therapy is being studied for diabetic foot ulcers in 2026: the wound-healing science, what the early evidence shows, FDA status, and safety notes.
The Cell-Free Shift in Regenerative Medicine: MSC, iPSC, and iMSC Exosomes
A June 2026 research update on the shift toward cell-free exosome therapeutics, comparing MSC-, iPSC-, and iMSC-derived exosomes, the clinical evidence, and why manufacturing quality is now the central challenge.
Research Update: New 2026 Review Maps Stem Cell Exosomes’ Expanding Role in Joint Regeneration
A May 2026 review in Molecular Biology Reports synthesizes a decade of evidence on stem cell-derived exosomes for joint regeneration. What the new paper says, the mechanisms it confirms, and what it means for patients evaluating exosome therapy for osteoarthritis and joint repair.
Exosomes and Biological Aging: 2026 Research on Senescence, SIRT1, and Tissue Repair
May 2026 research update on MSC-derived exosomes and biological aging: SIRT1 pathway activation, senescence signatures, skin/joint/cardiovascular aging, and what patients should look for in 2026.
Exosome Therapy for Brain Health: How MSC-Derived Exosomes Cross the Blood-Brain Barrier
How MSC-derived exosomes cross the blood-brain barrier to address neuroinflammation, cognitive decline, and stroke recovery. 2026 research and quality-sourcing guide.
May 2026 Regenerative Medicine Update: New Approvals and Phase III Trials Reshape the Field
May 2026 brought Japan’s first iPS cell approval for Parkinson’s, Capricor’s CAP-1002 BLA milestone, and continued Phase III enrollment in ExoFlo’s ARDS trial. Here is what the latest regenerative medicine news means for patients evaluating exosomes, stem cells, and peptide therapies right now.
The Exosome Standardization Crisis: Why Quality Standards Matter More Than Ever in 2026
A new April 2026 report values the exosome therapy market at $58.1 billion and flags a standardization crisis that puts sourcing and quality control at the center of every clinical decision.
Exosome Therapy Shows Promise for Severe Peripheral Nerve Injuries: 2026 Study Reveals Injury-Specific Benefits
A 2026 University of Miami study published in PLOS One found that Schwann cell-derived exosomes significantly improve nerve regeneration in severe peripheral nerve injuries, but not in milder crush injuries. Learn what this means for exosome therapy and regenerative medicine.